List of works by Robert C Doebele

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

scientific article published on 28 November 2018

A novel interplay between Epac/Rap1 and mitogen-activated protein kinase kinase 5/extracellular signal-regulated kinase 5 (MEK5/ERK5) regulates thrombospondin to control angiogenesis.

scientific article published on 26 August 2009

A novel interplay between Rap1 and PKA regulates induction of angiogenesis in prostate cancer

scientific article

A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer

scientific article

A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer

scientific article

A time to test, a time to treat

scientific article

Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents

scientific article published on January 2013

Activation of RAS family members confers resistance to ROS1 targeting drugs.

scientific article

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer

scientific article published on 8 April 2016

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

scientific article

Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed

scientific article published on April 2011

Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer

scientific article

Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cance

scientific article published on 26 January 2012

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

scientific article

Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer

scientific article published on 20 December 2012

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins

scientific article published on 11 December 2018

Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience

scientific article published on 9 September 2016

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

scientific article

Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.

scientific article

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer

scientific article

Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides

scientific article (publication date: August 2003)

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer

scientific article

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

scientific article published on 24 October 2016

Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status

scientific article published on 26 March 2016

Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer

scientific article

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

scientific article

Molecular pathways: ROS1 fusion proteins in cancer

scientific article

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014

scientific article

Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy

scientific article published on 10 September 2013

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer

scientific article published on 25 January 2010

Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions.

scientific article published on 29 December 2016

Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer

scientific article

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

scientific article

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer

scientific article

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.

scientific article published on 24 August 2015

ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.

scientific article

Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression

scientific article

Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents

scientific article published on May 2013

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

scientific article published on 09 August 2018

Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer.

scientific article published on 10 April 2018

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer

scientific article

Rociletinib in EGFR-mutated non-small-cell lung cancer

scientific article

Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib

scientific article

TRKing down an old oncogene in a new era of targeted therapy

scientific article

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer

scientific article

Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor

scientific article

Targeting ALK, ROS1, and BRAF kinases

scientific article published on December 2012

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

scientific article

Tarloxotinib is a hypoxia-activated pan-HER kinase inhibitor active against a broad range of HER-family oncogenes

scientific article published on 22 December 2020

The evolution of tumor classification: a role for genomics?

scientific article published on December 2013

The minority report: targeting the rare oncogenes in NSCLC

scientific article

Treating ALK-positive lung cancer--early successes and future challenges

scientific article published on 03 April 2012

Paulina is supported by:

About Paulina

Help